Nektar Therapeutics (0UNL.L)
USD 0.84
(0.63%)
USD 0.84
(0.63%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 16.1 Million USD | -16.15% |
| 2022 | 19.2 Million USD | 21.52% |
| 2021 | 15.8 Million USD | 3.33% |
| 2020 | 15.29 Million USD | 20.74% |
| 2019 | 12.66 Million USD | 11.28% |
| 2018 | 11.38 Million USD | 6.11% |
| 2017 | 10.72 Million USD | -3.45% |
| 2016 | 11.1 Million USD | -2.09% |
| 2015 | 11.34 Million USD | -12.4% |
| 2014 | 12.95 Million USD | -3.72% |
| 2013 | 13.45 Million USD | -26.37% |
| 2012 | 18.26 Million USD | 44.35% |
| 2011 | 12.65 Million USD | 74.18% |
| 2010 | 7.26 Million USD | 12.29% |
| 2009 | 6.47 Million USD | -30.56% |
| 2008 | 9.31 Million USD | -23.53% |
| 2007 | 12.18 Million USD | -16.85% |
| 2006 | 14.65 Million USD | -21.32% |
| 2005 | 18.62 Million USD | 74.23% |
| 2004 | 10.69 Million USD | 24.91% |
| 2003 | 8.55 Million USD | 35.66% |
| 2002 | 6.3 Million USD | 97.16% |
| 2001 | 3.2 Million USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | 0.0% |
| 1998 | - USD | 0.0% |
| 1997 | - USD | 0.0% |
| 1996 | - USD | 0.0% |
| 1995 | - USD | 0.0% |
| 1994 | - USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 14.46 Million USD | -10.92% |
| 2024 Q1 | 16.23 Million USD | 0.85% |
| 2023 Q2 | 20.68 Million USD | 2.24% |
| 2023 Q3 | 15.13 Million USD | -26.87% |
| 2023 Q4 | 16.1 Million USD | 6.42% |
| 2023 Q1 | 20.23 Million USD | 5.38% |
| 2023 FY | 16.1 Million USD | -16.15% |
| 2022 Q4 | 19.2 Million USD | 0.76% |
| 2022 Q1 | 15.37 Million USD | -2.67% |
| 2022 FY | 19.2 Million USD | 21.52% |
| 2022 Q3 | 19.05 Million USD | 12.3% |
| 2022 Q2 | 16.96 Million USD | 10.34% |
| 2021 Q4 | 15.8 Million USD | 3.07% |
| 2021 FY | 15.8 Million USD | 3.33% |
| 2021 Q1 | 16.8 Million USD | 9.91% |
| 2021 Q2 | 14.61 Million USD | -13.04% |
| 2021 Q3 | 15.33 Million USD | 4.89% |
| 2020 Q4 | 15.29 Million USD | 18.62% |
| 2020 Q2 | 12.58 Million USD | -12.12% |
| 2020 Q3 | 12.89 Million USD | 2.45% |
| 2020 Q1 | 14.32 Million USD | 13.07% |
| 2020 FY | 15.29 Million USD | 20.74% |
| 2019 Q4 | 12.66 Million USD | -7.69% |
| 2019 FY | 12.66 Million USD | 11.28% |
| 2019 Q1 | 11.77 Million USD | 3.49% |
| 2019 Q2 | 13.18 Million USD | 11.97% |
| 2019 Q3 | 13.72 Million USD | 4.03% |
| 2018 Q4 | 11.38 Million USD | -14.4% |
| 2018 Q1 | 10.67 Million USD | -0.48% |
| 2018 Q3 | 13.29 Million USD | 11.88% |
| 2018 FY | 11.38 Million USD | 6.11% |
| 2018 Q2 | 11.88 Million USD | 11.33% |
| 2017 Q1 | 13.01 Million USD | 17.17% |
| 2017 FY | 10.72 Million USD | -3.45% |
| 2017 Q4 | 10.72 Million USD | -21.44% |
| 2017 Q3 | 13.65 Million USD | 24.04% |
| 2017 Q2 | 11 Million USD | -15.43% |
| 2016 Q3 | 10.75 Million USD | 4.79% |
| 2016 FY | 11.1 Million USD | -2.09% |
| 2016 Q2 | 10.26 Million USD | -8.78% |
| 2016 Q1 | 11.25 Million USD | -0.85% |
| 2016 Q4 | 11.1 Million USD | 3.3% |
| 2015 FY | 11.34 Million USD | -12.4% |
| 2015 Q1 | 12.51 Million USD | -3.4% |
| 2015 Q2 | 10.12 Million USD | -19.08% |
| 2015 Q3 | 10.35 Million USD | 2.25% |
| 2015 Q4 | 11.34 Million USD | 9.6% |
| 2014 Q3 | 11.69 Million USD | -17.12% |
| 2014 Q2 | 14.11 Million USD | 9.63% |
| 2014 Q1 | 12.87 Million USD | -4.31% |
| 2014 Q4 | 12.95 Million USD | 10.75% |
| 2014 FY | 12.95 Million USD | -3.72% |
| 2013 Q3 | 15.07 Million USD | -26.38% |
| 2013 Q1 | 18.38 Million USD | 0.61% |
| 2013 Q4 | 13.45 Million USD | -10.77% |
| 2013 FY | 13.45 Million USD | -26.37% |
| 2013 Q2 | 20.47 Million USD | 11.41% |
| 2012 Q1 | 14.1 Million USD | 11.47% |
| 2012 FY | 18.26 Million USD | 44.35% |
| 2012 Q4 | 18.26 Million USD | 9.04% |
| 2012 Q3 | 16.75 Million USD | 13.86% |
| 2012 Q2 | 14.71 Million USD | 4.3% |
| 2011 Q1 | 11.71 Million USD | 61.19% |
| 2011 FY | 12.65 Million USD | 74.18% |
| 2011 Q4 | 12.65 Million USD | 18.79% |
| 2011 Q3 | 10.65 Million USD | 8.75% |
| 2011 Q2 | 9.79 Million USD | -16.35% |
| 2010 Q1 | 8.7 Million USD | 34.49% |
| 2010 FY | 7.26 Million USD | 12.29% |
| 2010 Q3 | 11.46 Million USD | 17.21% |
| 2010 Q2 | 9.77 Million USD | 12.34% |
| 2010 Q4 | 7.26 Million USD | -36.6% |
| 2009 Q4 | 6.47 Million USD | -27.54% |
| 2009 Q2 | 10.11 Million USD | -24.51% |
| 2009 FY | 6.47 Million USD | -30.56% |
| 2009 Q1 | 13.39 Million USD | 43.71% |
| 2009 Q3 | 8.93 Million USD | -11.67% |
| 2008 Q1 | 11.02 Million USD | -9.52% |
| 2008 FY | 9.31 Million USD | -23.53% |
| 2008 Q2 | 10.16 Million USD | -7.81% |
| 2008 Q3 | 9.86 Million USD | -3.0% |
| 2008 Q4 | 9.31 Million USD | -5.5% |
| 2007 Q4 | 12.18 Million USD | -29.04% |
| 2007 FY | 12.18 Million USD | -16.85% |
| 2007 Q1 | 16.77 Million USD | 14.42% |
| 2007 Q2 | 17.22 Million USD | 2.73% |
| 2007 Q3 | 17.17 Million USD | -0.31% |
| 2006 FY | 14.65 Million USD | -21.32% |
| 2006 Q1 | 33.18 Million USD | 78.13% |
| 2006 Q4 | 14.65 Million USD | -7.21% |
| 2006 Q3 | 15.79 Million USD | -2.78% |
| 2006 Q2 | 16.24 Million USD | -51.03% |
| 2005 Q4 | 18.62 Million USD | 41.63% |
| 2005 Q1 | 10.68 Million USD | -0.07% |
| 2005 FY | 18.62 Million USD | 74.23% |
| 2005 Q2 | 12.78 Million USD | 19.64% |
| 2005 Q3 | 13.15 Million USD | 2.9% |
| 2004 Q2 | 10.31 Million USD | 0.0% |
| 2004 FY | 10.69 Million USD | 24.91% |
| 2004 Q4 | 10.69 Million USD | 2.07% |
| 2004 Q3 | 10.47 Million USD | 1.51% |
| 2004 Q1 | - USD | -100.0% |
| 2003 Q4 | 8.55 Million USD | 12.32% |
| 2003 Q3 | 7.62 Million USD | 36.93% |
| 2003 Q2 | 5.56 Million USD | -4.45% |
| 2003 Q1 | 5.82 Million USD | -7.69% |
| 2003 FY | 8.55 Million USD | 35.66% |
| 2002 Q4 | 6.3 Million USD | 26.31% |
| 2002 Q2 | 4.61 Million USD | 25.51% |
| 2002 Q1 | 3.67 Million USD | 14.91% |
| 2002 Q3 | 4.99 Million USD | 8.23% |
| 2002 FY | 6.3 Million USD | 97.16% |
| 2001 Q3 | 3.27 Million USD | -12.08% |
| 2001 Q4 | 3.2 Million USD | -2.26% |
| 2001 FY | 3.2 Million USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 Q2 | 3.72 Million USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1999 Q4 | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1998 Q4 | - USD | 0.0% |
| 1998 Q2 | - USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| 1998 Q1 | - USD | 0.0% |
| 1998 Q3 | - USD | 0.0% |
| 1997 Q4 | - USD | 0.0% |
| 1997 Q1 | - USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| 1997 Q2 | - USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| 1996 Q3 | - USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| 1996 Q1 | - USD | 0.0% |
| 1996 Q4 | - USD | 0.0% |
| 1996 Q2 | - USD | 0.0% |
| 1995 FY | - USD | 0.0% |
| 1995 Q1 | - USD | 0.0% |
| 1995 Q2 | - USD | 0.0% |
| 1995 Q3 | - USD | 0.0% |
| 1995 Q4 | - USD | 0.0% |
| 1994 FY | - USD | 0.0% |
| 1994 Q3 | - USD | 0.0% |
| 1994 Q4 | - USD | 0.0% |
| 1994 Q1 | - USD | 0.0% |
| 1994 Q2 | - USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| uniQure N.V. | 12.02 Million USD | -33.907% |
| Agios Pharmaceuticals, Inc. | 19.07 Million USD | 15.596% |
| Amicus Therapeutics, Inc. | 59.69 Million USD | 73.028% |
| Atara Biotherapeutics, Inc. | 9.7 Million USD | -65.887% |
| bluebird bio, Inc. | 22.91 Million USD | 29.748% |
| Cara Therapeutics, Inc. | 2.82 Million USD | -470.755% |
| Imunon, Inc. | - USD | -Infinity% |
| Editas Medicine, Inc. | - USD | -Infinity% |
| IQVIA Holdings Inc. | - USD | -Infinity% |
| Mettler-Toledo International Inc. | 385.86 Million USD | 95.827% |
| Myriad Genetics, Inc. | 20.1 Million USD | 19.896% |
| Neurocrine Biosciences, Inc. | 38.3 Million USD | 57.961% |
| Supernus Pharmaceuticals, Inc. | 77.4 Million USD | 79.2% |
| Verastem, Inc. | - USD | -Infinity% |
| Walgreens Boots Alliance, Inc. | 8.32 Billion USD | 99.806% |
| Waters Corporation | 516.23 Million USD | 96.881% |
| Thermo Fisher Scientific Inc. | 5.08 Billion USD | 99.684% |
| Biogen Inc. | 2.52 Billion USD | 99.363% |
| Perrigo Company plc | 1.14 Billion USD | 98.589% |
| Dynavax Technologies Corporation | 53.29 Million USD | 69.786% |
| Illumina, Inc. | 587 Million USD | 97.257% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Iovance Biotherapeutics, Inc. | 10.37 Million USD | -55.235% |
| Heron Therapeutics, Inc. | 42.11 Million USD | 61.764% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 1.1 Billion USD | 98.546% |
| Sangamo Therapeutics, Inc. | - USD | -Infinity% |
| Evolus, Inc. | 10.99 Million USD | -46.399% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Aclaris Therapeutics, Inc. | - USD | -Infinity% |
| Regeneron Pharmaceuticals, Inc. | 2.58 Billion USD | 99.376% |
| Esperion Therapeutics, Inc. | 65.62 Million USD | 75.464% |
| FibroGen, Inc. | 41.56 Million USD | 61.263% |
| Agilent Technologies, Inc. | 1.03 Billion USD | 98.438% |
| OPKO Health, Inc. | 65.69 Million USD | 75.492% |
| Homology Medicines, Inc. | - USD | -Infinity% |
| Geron Corporation | - USD | -Infinity% |
| Alnylam Pharmaceuticals, Inc. | 89.14 Million USD | 81.939% |
| Exelixis, Inc. | 17.32 Million USD | 7.054% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | - USD | -Infinity% |
| Zoetis Inc. | 2.56 Billion USD | 99.372% |
| Axsome Therapeutics, Inc. | 15.13 Million USD | -6.383% |
| Abeona Therapeutics Inc. | -2.44 Million USD | 758.797% |
| Vertex Pharmaceuticals Incorporated | 738.8 Million USD | 97.821% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 28.42 Million USD | 43.356% |
| Sarepta Therapeutics, Inc. | 322.85 Million USD | 95.013% |
| Corcept Therapeutics Incorporated | 7.73 Million USD | -108.292% |
| Halozyme Therapeutics, Inc. | 127.6 Million USD | 87.382% |
| Blueprint Medicines Corporation | 21.22 Million USD | 24.134% |
| Insmed Incorporated | 83.24 Million USD | 80.659% |
| TG Therapeutics, Inc. | 39.82 Million USD | 59.569% |
| Incyte Corporation | 62.97 Million USD | 74.431% |
| Emergent BioSolutions Inc. | 328.9 Million USD | 95.105% |